Kuros Biosciences (KURN) Q3 2025 TU earnings summary

Executive summary

• Achieved a 77% year-over-year increase in total medical device sales for the first nine months of 2025, reaching USD 101.1 million.

• Direct Magnetos sales rose 76% year-over-year to USD 99.7 million for the same period.

• EBITDA increased to USD 7.4 million from USD 1.6 million year-over-year; adjusted EBITDA reached USD 12.2 million, with a margin of 12.1%.

• Cash position improved to USD 20.0 million as of September 30, 2025, despite ongoing investments in working capital and strategic initiatives.

Financial highlights

• Total group revenue for the first nine months of 2025 was USD 101.1 million, up 77% compared to the same period in 2024.

• Adjusted EBITDA margin increased to 12.1% from 11.3% year-over-year.

• Cash and cash equivalents rose to USD 20.0 million from USD 18.4 million at the end of June 2025.

Outlook and guidance

• Sales guidance for 2025 raised, now expecting growth of at least 70% for the year.

• Second half sales expected to align with usual seasonal trends.